Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to a newly hired non-executive employee on June 2, 2025. The options cover 2,500 shares of common stock with an exercise price of $11.45, matching the closing price on Nasdaq Global Select Market on the grant date. The options were granted under the 2021 Inducement Plan as a material inducement for employment compensation. The vesting schedule spans three years, with one-third of shares vesting annually, contingent on continuous service. The options expire after ten years and were granted without stockholder approval.

BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com

FAQ

What stock options did Anika Therapeutics (ANIK) grant to its new employee in June 2025?

Anika granted 2,500 non-statutory stock options at an exercise price of $11.45 per share to one newly hired non-executive employee.

What is the vesting schedule for ANIK's June 2025 inducement stock options?

The options vest over three years, with one-third of the shares vesting on each of the first three anniversaries of the grant date, subject to continuous service.

When do the ANIK inducement stock options granted in June 2025 expire?

The stock options will expire on the tenth anniversary of the grant date (June 2, 2035), unless terminated earlier.

Was stockholder approval required for ANIK's 2021 Inducement Plan stock options?

No, the stock options granted under the Anika Therapeutics 2021 Inducement Plan were not subject to stockholder approval.